10-Q

_______________________________________________________

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

_____________________________

FORM 10-Q

[X] Quarterly Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2008
OR
[ ] Transition Report Pursuant to Section 13 or 15(d) of
the Securities and Exchange Act of 1934
For the transition period from
______ to ______


Commission File Number: 000-30406

HEALTHTRONICS, INC.
(Exact name of registrant as specified in its charter)

GEORGIA	58-2210668
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

9825 Spectrum Drive, Building 3, Austin, TX 78717
           (Address of principal executive office)                (Zip code)

(512) 328-2892
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES   X  NO     

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer   ¨              Accelerated Filer   x             Non-Accelerated Filer   ¨             Smaller reporting company   ¨ (Do not check if a smaller reporting company)  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES      NO  X  

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Title of Each Class
     Common Stock, no par value Number of Shares Outstanding at
November 1, 2008
36,468,096

PART I

FINANCIAL INFORMATION

Item 1 - Financial Statements

-2-

HEALTHTRONICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

($ in thousands, except per share data)	Three Months Ended September 30,						Nine Months Ended September 30,
	2008			2007			2008			2007
Revenue:
Urology Services	$	39,135		$	31,625		$	106,550		$	90,846
Medical Products		5,636			4,176			14,467			13,002
Other		--			154			288			421
Total revenue		44,771			35,955			121,305			104,269
Cost of services and general and administrative expenses:
Urology Services		16,899			13,160			47,289			40,126
Medical Products		3,055			2,834			6,968			8,077
Selling, general & administrative		4,600			4,052			14,186			12,959
Depreciation and amortization		3,073			2,747			8,770			8,339
		27,627			22,793			77,213			69,501
Operating income		17,144			13,162			44,092			34,768
Other income (expenses):
Interest and dividends		806			247			1,098			835
Interest expense		(182	)		(196	)		(591	)		(644	)
		624			51			507			191
Income from continuing operations before provision
for income taxes and minority interest		17,768			13,213			44,599			34,959
Minority interest in consolidated income		15,552			12,214			40,380			32,998
Provision for income taxes		889			389			1,730			956
Income from continuing operations		1,327			610			2,489			1,005
Gain (loss) from discontinued operations, net of tax		--			135			--			(111	)
Net income	$	1,327		$	745		$	2,489		$	894
Basic earnings per share:
Income from continuing operations	$	0.04		$	0.02		$	0.07		$	0.03
Gain (loss) from discontinued operations		--			--			--			--
Net income	$	0.04		$	0.02		$	0.07		$	0.03
Weighted average shares outstanding		37,503			35,425			36,666			35,419
Diluted earnings per share:
Income from continuing operations	$	0.04		$	0.02		$	0.07		$	0.03
Gain (loss) from discontinued operations		--			--			--			--
Net income	$	0.04		$	0.02		$	0.07		$	0.03
Weighted average shares outstanding		37,604			35,425			36,734			35,423

See accompanying notes to condensed consolidated financial statements.

-3-

HEALTHTRONICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

($ in thousands)	September 30, 2008			December 31, 2007
ASSETS
Current assets:
Cash and cash equivalents	$	18,434		$	25,198
Accounts receivable, less allowance for doubtful
accounts of $2,415 in 2008 and $2,368 in 2007		26,782			21,889
Other receivables		6,132			2,703
Deferred income taxes		13,459			12,547
Prepaid expenses and other current assets		2,291			1,656
Inventory		9,980			10,221
Total current assets		77,078			74,214
Property and equipment:
Equipment, furniture and fixtures		53,912			47,751
Building and leasehold improvements		6,060			12,437
		59,972			60,188
Less accumulated depreciation and
amortization		(28,740	)		(27,169	)
Property and equipment, net		31,232			33,019
Other investments		1,844			1,353
Goodwill, at cost		234,796			217,505
Intangible assets		5,852			5,220
Other noncurrent assets		2,918			4,745
	$	353,720		$	336,056

See accompanying notes to condensed consolidated financial statements.

-4-

HEALTHTRONICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (continued)
(Unaudited)

($ in thousands, except share data)	September 30, 2008			December 31, 2007
LIABILITIES
Current liabilities:
Current portion of long-term debt	$	2,804		$	4,332
Accounts payable		5,225			5,859
Accrued distributions to minority interests		95			226
Accrued expenses		8,171			7,275
Total current liabilities		16,295			17,692
Long-term debt, net of current portion		9,308			4,194
Other long term obligations		53			75
Deferred income taxes		29,911			30,024
Total liabilities		55,567			51,985
Minority interest		44,249			41,653
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value, 30,000,000 shares authorized: none outstanding
Common stock, no par value, 70,000,000 authorized: 38,272,888 issued in 2008
and 38,168,096 outstanding in 2008; 35,610,236 issued in 2007 and
35,560,097 outstanding in 2007		211,257			202,049
Accumulated earnings		43,330			40,841
Treasury stock, at cost, 104,792 shares in 2008 and 50,139 shares in 2007		(683	)		(472	)
Total stockholders' equity		253,904			242,418
	$	353,720		$	336,056

See accompanying notes to condensed consolidated financial statements.

-5-

HEALTHTRONICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Nine Months Ended September 30,
($ in thousands)	2008			2007
CASH FLOWS FROM OPERATING ACTIVITIES:
Fee and other revenue collected	$	122,803		$	108,005
Cash paid to employees, suppliers of goods and others		(70,125	)		(61,433	)
Interest received		374			835
Interest paid		(560	)		(642	)
Taxes paid		(1,187	)		(903	)
Discontinued operations		--			(298	)
Net cash provided by operating activities		51,305			45,564
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of entities, net of cash acquired		(17,270	)		(7,976	)
Purchases of equipment and leasehold improvements		(8,762	)		(6,838	)
Proceeds from sales of assets		8,755			1,017
Other		(236	)		(18	)
Discontinued operations		--			1,335
Net cash used in investing activities		(17,513	)		(12,480	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Borrowings on notes payable		13,547			2,546
Payments on notes payable, exclusive of interest		(10,561	)		(4,483	)
Distributions to minority interest		(42,797	)		(35,697	)
Contributions by minority interest, net of buyouts		(534	)		168
Purchase of treasury stock		(211	)		--
Discontinued operations		--			(20	)
Net cash used in financing activities		(40,556	)		(37,486	)
NET DECREASE IN CASH AND CASH EQUIVALENTS		(6,764	)		(4,402	)
Cash and cash equivalents, beginning of period, includes cash
from discontinued operations of $(198) for December 31, 2006		25,198			27,659
Cash and cash equivalents, end of period	$	18,434		$	23,257

See accompanying notes to condensed consolidated financial statements.

-6-

HEALTHTRONICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
(Unaudited)

	Nine Months Ended September 30,
($ in thousands)	2008			2007
Reconciliation of net income to net cash provided by operating activities:
Net income	$	2,489		$	894
Adjustments to reconcile net income
to net cash provided by operating activities
Minority interest in consolidated income		40,380			32,998
Depreciation and amortization		8,770			8,339
Provision for uncollectible accounts		(42	)		(8	)
Provision for deferred income taxes		918			3,200
Non-cash share based compensation		2,470			1,204
Other		(910	)		7
Discontinued Operations		--			(117	)
Changes in operating assets and liabilities,
net of effect of purchase transactions
Accounts receivable		(493	)		1,764
Other receivables		1,106			(512	)
Other assets		(98	)		1,656
Accounts payable		(2,534	)		(639	)
Accrued expenses		(751	)		(3,222	)
Total adjustments		48,816			44,670
Net cash provided by operating activities	$	51,305		$	45,564

See accompanying notes to condensed consolidated financial statements.

-7-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

1. General

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with the accounting principles for interim financial statements and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These condensed consolidated financial statements reflect all adjustments which are, in our opinion, necessary for a fair presentation of the statement of the financial position as of September 30, 2008 and the results of operations and cash flows for the periods presented. Such adjustments are of a normal recurring nature unless otherwise noted herein. The operating results for the interim periods are not necessarily indicative of results for the full fiscal year.

The notes to consolidated financial statements appearing in our Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission should be read in conjunction with this Quarterly Report on Form 10-Q. There have been no significant changes in the information reported in those notes other than from normal business activities and as discussed herein.

Certain reclassifications have been made to expense categories presented in 2007 to be consistent with the 2008 presentation. In 2007, we classified our operating expenses in the accompanying condensed consolidated statements of income by nature using the following categories: Salaries, wages and benefits; Other cost of services; General and administrative; Legal and professional; Manufacturing costs; Advertising; and Other. In 2008, in order to more closely match each class of revenue we have reclassified our operating expense categories by function as follows: Urology services, Medical products, and Sales, general & administrative. These reclassifications were between operating expense categories and did not change total operating expense in any period.

During the fourth quarter of 2006, we committed to a plan to sell our Rocky Mountain Prostate business and announced our decision to discontinue our involvement in the clinical trials of the Ablatherm device. Accordingly, these activities have been reflected as discontinued operations in the accompanying condensed consolidated financial statements. In September 2007, we completed the sale of our Rocky Mountain Prostate business.

2. Debt

Senior Credit Facility

Our senior credit facility is comprised of a five-year $60 million revolving line of credit and a $125 million senior secured term loan B due 2011. We entered into this senior credit facility in March 2005 and amended it in April 2008. The loan bears interest at a variable rate equal to LIBOR + 1.25 to 2.25% or prime + .25 to 1.25%. On July 31, 2006, we used a portion of the proceeds from the sale of our specialty vehicle manufacturing segment to repay the term loan B in full. As of September 30, 2008, we had $6 million drawn on the revolving line of credit. Our senior credit facility contains covenants that, among other things, limit our ability to incur debt, create liens, make investments, sell assets, pay dividends, make capital expenditures, make restricted payments, enter into transactions with affiliates, and make acquisitions. In addition, our facility requires us to maintain certain financial ratios. We were in compliance with the covenants under our senior credit facility as of September 30, 2008.

-8-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

On April 14, 2008, we amended our senior credit facility to (1) increase the revolving line of credit from $50 million to $60 million, (2) create an exception to the restricted payments negative covenant of the senior credit facility to enable us to repurchase up to $10 million of our common stock, through a stock repurchase program or otherwise, (3) increase the dollar amount of permitted acquisitions under the acquisitions negative covenant of the senior credit facility from $25 million to $30 million during any twelve month period beginning after April 14, 2008 and (4) create an exception from the calculation of such permitted acquisitions basket for our acquisition of Advanced Medical Partners, Inc. (“AMPI”).

Other

As of September 30, 2008, we had notes payable totaling $6.1 million related to equipment purchased by our limited partnerships. These notes payable are paid down from the cash flows of the related partnerships. They generally bear interest at LIBOR or prime plus a certain premium and have various due dates over the next three years.

3. Earnings per share

Basic earnings per share (“EPS”) is based on weighted average shares outstanding without any dilutive effects considered. Diluted EPS reflects dilution from all contingently issuable shares, including options, non-vested stock awards and warrants. A reconciliation of such EPS data is as follows:

($ in thousands, except per share data)	Basic earnings per share		Diluted earnings per share
Nine Months Ended September 30, 2008
Net income	$	2,489	$	2,489
Weighted average shares outstanding		36,666		36,666
Effect of dilutive securities		--		68
Shares for EPS calculation		36,666		36,734
Net income per share	$	0.07	$	0.07
Nine Months Ended September 30, 2007
Net income	$	894	$	894
Weighted average shares outstanding		35,419		35,419
Effect of dilutive securities		--		4
Shares for EPS calculation		35,419		35,423
Net income per share	$	0.03	$	0.03

-9-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

($ in thousands, except per share data)	Basic earnings per share		Diluted earnings per share
Three Months Ended September 30, 2008
Net income	$	1,327	$	1,327
Weighted average shares outstanding		37,503		37,503
Effect of dilutive securities		--		101
Shares for EPS calculation		37,503		37,604
Net income per share	$	0.04	$	0.04
Three Months Ended September 30, 2007
Net income	$	745	$	745
Weighted average shares outstanding		35,425		35,425
Effect of dilutive securities		--		--
Shares for EPS calculation		35,425		35,425
Net income per share	$	0.02	$	0.02

We did not include in our computation of diluted EPS unexercised stock options and non-vested stock awards to purchase 2,997,000 and 3,487,000 shares of our common stock as of September 30, 2008 and 2007, respectively, because the effect would be antidilutive. In May 2008, our shareholders approved an amendment to our 2004 Equity Incentive Plan to increase by 2,850,000 shares the number of shares available for issuance thereunder from 2,950,000 to 5,800,000 shares.

4. Segment Reporting

We have two reportable segments: urology services and medical products. The urology services segment provides services related to the operation of lithotripters, including scheduling, staffing, training, quality assurance, maintenance, regulatory compliance and contracting with payors, hospitals and surgery centers. Also in the urology segment, we provide treatments for benign and cancerous conditions of the prostate. In treating benign prostate disease, we deploy three technologies: (1) photo-selective vaporization of the prostate (PVP), (2) trans-urethral needle ablation (TUNA), and (3) trans-urethral microwave therapy (TUMT) in certain partnerships. All three technologies apply an energy source which reduces the size of the prostate gland. For treating prostate and other cancers, we use a procedure called cryosurgery, a process which uses a double freeze thaw cycle to destroy cancers cells. Our medical products segment sells and maintains lithotripters and their related consumables. We are also the exclusive U.S. distributor of the Revolix branded laser. The operations of our pathology laboratories are also included in our medical products segment.

-10-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

We measure performance based on the pretax income or loss from our operating segments, which does not include unallocated corporate general and administrative expenses or corporate interest income and expense.

($ in thousands)	Urology Services		Medical Products
Nine Months Ended September 30, 2008
Revenue from external customers	$	106,550	$	14,467
Intersegment revenues		--		7,711
Segment profit		8,776		2,456
Nine Months Ended September 30, 2007
Revenue from external customers	$	90,846	$	13,002
Intersegment revenues		--		6,895
Segment profit		7,210		64

The following is a reconciliation of the measure of segment profit per above to consolidated income before provision for income taxes per the condensed consolidated statements of income:

	Nine Months ended September 30,
($ in thousands)	2008			2007
Total segment profit	$	11,232		$	7,274
Unallocated corporate revenues		288			421
Unallocated corporate expenses:
General and administrative		(7,661	)		(5,599	)
Net interest income (expense)		639			408
Other, net		(279	)		(543	)
Total unallocated corporate expenses		(7,301	)		(5,734	)
Income before income taxes	$	4,219		$	1,961

-11-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

($ in thousands)	Urology Services		Medical Products
Three Months Ended September 30, 2008
Revenue from external customers	$	39,135	$	5,636
Intersegment revenues		--		2,481
Segment profit		3,307		580
Three Months Ended September 30, 2007
Revenue from external customers	$	31,625	$	4,176
Intersegment revenues		--		2,093
Segment profit		2,768		47

The following is a reconciliation of the measure of segment profit per above to consolidated income before provision for income taxes per the condensed consolidated statements of income:

	Three Months ended September 30,
($ in thousands)	2008			2007
Total segment profit	$	3,887		$	2,815
Unallocated corporate revenues		--			154
Unallocated corporate expenses:
General and administrative		(2,288	)		(1,898	)
Net interest income (expense)		670			105
Other, net		(53	)		(177	)
Total unallocated corporate expenses		(1,671	)		(1,970	)
Income before income taxes	$	2,216		$	999

5. Stock-Based Compensation

On January 1, 2006, we adopted Statement of Financial Accounting Standard (“SFAS”) No. 123(R), Share-Based Payment, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including stock option grants based on estimated fair values. SFAS No. 123(R) requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the award’s portion that is ultimately expected to vest is recognized as expense over the requisite service periods. Prior to the adoption of SFAS No. 123(R), we accounted for share-based awards to employees and directors using the intrinsic value method in accordance with Accounting Principles Board Opinion (“APB”) No. 25 as allowed under SFAS No. 123, Accounting for Stock-Based Compensation. Under the intrinsic value method, share-based compensation expense was only recognized by us if the exercise price of the stock option was less than the fair market value of the underlying stock at the date of grant.

-12-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

In the first quarter of 2008, we granted a total of 675,166 of non-vested shares under our 2004 Equity Incentive Plan. 80,000 shares vest 25% on each of the first four anniversaries of the grant date. 386,857 shares vest based on the achievement of the performance targets outlined below. 208,309 shares vest 25% on each of the first four anniversaries of the grant date; however, their vesting can be accelerated if the following performance targets are reached.

Percent of Grant Vesting	Performance Target (% increase over grant price)
25%	15%
25%	30%
25%	45%
25%	60%

On May 5, 2008, the first performance target related to one of the grants was met and as a result 92,862 of the non-vested stock awards vested, which resulted in the recognition of approximately $307,000 in share based compensation cost. On August 25, 2008, the second performance target was met resulting in the vesting of an additional 92,862 shares and the recognition of approximately $118,000 in share based compensation cost.

As of September 30, 2008, unrecognized share-based compensation cost related to unvested stock options was approximately $1.8 million, which is expected to be recognized over a weighted average period of approximately 1.4 years. We also had $1.2 million of unrecognized compensation costs related to non-vested stock awards as of September 30, 2008, which is expected to be recognized over a weighted average period of approximately 1.7 years. We have included approximately $2.5 million and $0.8 million for share-based compensation cost in the accompanying condensed consolidated statements of income for the nine months ended September 30, 2008 and 2007, respectively.

Share-based compensation expense recognized during the quarters ended September 30, 2008 and 2007 is related to awards granted prior to, but not yet fully vested as of, January 1, 2006 and awards granted subsequent to December 31, 2005. We have historically and continue to estimate the fair value of stock options using the Black-Scholes-Merton (“Black Scholes”) option-pricing model. For our non-vested stock awards, we relied upon a closed-form barrier option valuation model, which is a derivation of the Black Scholes model to determine the fair value of the awards and utilized a lattice model to analyze the appropriate service period.

6. Inventory

As of September 30, 2008 and December 31, 2007, inventory consisted of the following:

-13-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

($ In thousands)	September 30, 2008		December 31, 2007
Raw Materials	$	6,486	$	6,144
Finished Goods		3,494		4,077
	$	9,980	$	10,221

7. Discontinued Operations

In November 2006, we announced our decision to discontinue our involvement in the clinical trials of the Ablatherm device (HIFU) manufactured by EDAP TMS S.A. (EDAP). This decision results in our forfeiting the exclusive rights in the United States, when and if a Pre-Market Approval is granted by the FDA and forfeiting our rights to earn additional warrants to acquire EDAP common stock. We have accordingly included our costs related to the clinical trials in discontinued operations in the accompanying condensed consolidated statements of income.

In the fourth quarter of 2006, we committed to a plan to sell our Rocky Mountain Prostate Thermotherapies (“RMPT”) business. In July 2007, we entered into a purchase agreement to sell the RMPT business for $1.35 million. This sale closed on September 28, 2007. We classified this business as held for sale and included its results from operations in discontinued operations.

The following table details selected financial information included in results from discontinued operations in the condensed consolidated statements of income for the three and nine month periods ended September 30, 2007.

Condensed Consolidated Statements of Income
($ in thousands)	2007
For the Nine Months Ended September 30
Revenue
Rocky Mountain Prostate Thermotherapies	$	3,268
HIFU		--
Cost of services
Rocky Mountain Prostate Thermotherapies		(3,694	)
HIFU		(209	)
Gain on sale of Rocky Mountain Prostate
Thermotherapies		454
Income tax benefit		70
Discontinued operations, net of tax	$	(111	)

-14-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

Condensed Consolidated Statements of Income
($ in thousands)	2007
For the Three Months Ended September 30
Revenue
Rocky Mountain Prostate Thermotherapies	$	1,031
HIFU		--
Cost of services
Rocky Mountain Prostate Thermotherapies		(1,255	)
HIFU		(10	)
Gain on sale of Rocky Mountain Prostate
Thermotherapies		454
Income tax benefit		(85	)
Discontinued operations, net of tax	$	135

8. New Pronouncements

In May 2008, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS No. 162”), The Hierarchy of Generally Accepted Accounting Principles. SFAS 162 identifies the sources of accounting principles and the framework for selecting the principles used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles in the United States (the GAAP hierarchy). SFAS 162 will become effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles. Based on our current operations, we do not expect that the adoption of SFAS 162 will have a material impact on our financial position or results of operations.

In December 2007, the FASB issued Statement of Financial Accounting Standards (“SFAS”) No. 141 (revised 2007), "Business Combinations", (“SFAS 141R”). SFAS 141R establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, including goodwill, the liabilities assumed and any non-controlling interest in the acquiree. The Statement also establishes disclosure requirements to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS 141R is effective for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. The impact of adopting SFAS 141R will be dependent on the future business combinations that we may pursue after its effective date.

In December 2007, the FASB issued SFAS No. 160, "Noncontrolling Interests in Consolidated Financial Statements–an amendment of ARB No. 51" (“SFAS 160”). This Statement amends ARB 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. SFAS 160 requires companies to report a noncontrolling interest in a subsidiary as equity. Additionally, companies are required to include amounts attributable to both the parent and the noncontrolling interest in the consolidated net income and provide disclosure of net income attributable to the parent and to the noncontrolling interest on the face of the consolidated statement of income. This Statement clarifies that after control is obtained, transactions which change ownership but do not result in a loss of control are accounted for as equity transactions. Prior to this Statement being issued, decreases in a parent’s ownership interest in a subsidiary could be accounted for as equity transactions or as transactions with gain or loss recognition in the income statement. A change in ownership of a consolidated subsidiary that results in a loss of control and deconsolidation would result in a gain or loss in net income. SFAS 160 is effective for fiscal years beginning on or after December 15, 2008 with earlier adoption prohibited. The adoption of SFAS 160 will revise our presentation of consolidated financial statements and further impact will be dependent on our future changes in ownership in subsidiaries after the effective date.

-15-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities – Including an amendment of FASB Statement No. 115” ("SFAS 159"). SFAS 159 expands the use of fair value accounting to many financial instruments and certain other items. The fair value option is irrevocable and generally made on an instrument-by-instrument basis, even if a company has similar instruments that it elects not to measure based on fair value. SFAS 159 is effective for fiscal years beginning after November 15, 2007. The adoption of SFAS 159 did not have a material impact on our financial position or results of operations.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" (“SFAS 157”). SFAS 157 defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. SFAS 157 is effective for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. In December 2007, the FASB released a proposed FASB Staff Position (FSP FAS 157-b–Effective Date of FASB Statement No. 157) which, if adopted as proposed, would delay the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). In February 2008, the FASB issued FASB Staff Position FAS 157-2, “Effective Date of FASB Statement No. 157” (the “FSP”). The FSP delayed, for one year, the effective date of FAS 157 for all nonfinancial assets and liabilities, except those that are recognized or disclosed in the financial statements on at least an annual basis. The implementation of SFAS No. 157 for financial assets and financial liabilities, effective January 1, 2008, did not have a material impact on our consolidated financial position and results of operations.

9. Acquisitions

On July 15, 2008, we acquired UroPath, LLC (“UroPath”) for $7.5 million in cash. Founded in 2003, UroPath is a leading provider of anatomical pathology laboratory services in the U.S. with locations in Florida, Texas, and Pennsylvania. Based on our preliminary allocation of the purchase price, we recorded approximately $6.3 million of goodwill related to this transaction, all of which is tax deductible.

On April 17, 2008, we completed the acquisition of AMPI pursuant to the Stock Purchase Agreement dated March 18, 2008 between us, Litho Management, Inc., AMPI and the stockholders of AMPI. Founded in 2003, AMPI is a leading provider of urological cryosurgery services in the U.S. with operations in 46 states. We acquired the outstanding shares of capital stock of AMPI (other than shares already held by us) for a purchase price of approximately $6.9 million in cash and approximately 1.8 million shares of our common stock, plus a two-year earn-out based on the future achievement of EBITDA. We determined the value of our common stock by using an average closing price for the two trading days prior to and after the public announcement of the merger. Based upon our preliminary allocation of the purchase price, we recognized $12.8 million of goodwill related to this transaction, all of which is not tax deductible.

-16-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

In 2008, we increased our ownership in two partnerships and purchased a small service company for an aggregate purchase price of approximately $3.7 million. We recorded approximately $2.9 million of goodwill related to these transactions, all of which is tax deductible.

Our unaudited proforma combined income data for the periods ended September 30, 2008 and 2007, assuming the acquisitions were effective January 1, of each year, is as follows:

	Nine Months Ended September 30,
($ in thousands, except per share data)	2008			2007
Total revenues	$	132,078		$	131,637
Total expenses		(129,065	)		(128,728	)
Discontinued Operations		--			(111	)
Net income	$	3,013		$	2,798
Diluted earnings per share	$	0.08		$	0.08

10. Unrecognized Tax Benefits

As a result of the merger in 2004 in which Prime Medical Services, Inc. (“Prime”) completed a merger with HealthTronics Surgical Services, Inc. (“HSS”) pursuant to which Prime merged with and into HSS, with HealthTronics, Inc. as the surviving corporation, we acquired certain tax benefits, a portion of which were subject to limitations imposed by Section 382 of the Internal Revenue Code. Due to the uncertainty of our ability to realize these tax benefits, there was no recognition of them in our purchase accounting at that time.

In October, 2005, we filed income tax refund claims related to HSS’s previously filed 2000 - 2003 federal income tax returns. In late September 2008, the Internal Revenue Service (“IRS”) completed examinations of our 2000 - 2006 federal income tax returns. As a result of the examinations, $2.3 million of previously unrecognized tax benefits were recognized and recorded as a reduction of goodwill in the third quarter of 2008. In October, 2008, we received $5.2 million from the IRS, a portion representing tax refunds of $4.3 million and a portion representing interest income of $888,000. The tax refund of $4.3 million and interest income in the amount of $165,000 was recorded as a reduction of goodwill while the interest income earned subsequent to the merger, totaling $723,000, has been recorded in the accompanying Condensed Consolidated Statements of Income.

-17-

HEALTHTRONICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2008
(Unaudited)

The tax benefits mentioned above in the first paragraph of this note 10 include built-in losses that are available to offset future taxable income of approximately $12.4 million and net operating loss carry forwards that are available to offset future taxable income through 2027 of approximately $67.9 million. As a result of the completion of the IRS examination during the quarter, the tax affected amount of these tax benefits, which totals $30.6 million, has been recorded as deferred tax assets on our balance sheet. In accordance with the provisions of Statement of Financial Accounting Standards No. 109, a valuation allowance of $30.6 million was established in the third quarter of 2008 due to the uncertainty in our ability to realize these tax benefits.

11. Subsequent Events

On October 10, 2008, we entered into a Stock Purchase Agreement with Atlantic Urological Associates (“AUA”), pursuant to which we purchased the outstanding shares of capital stock of Ocean Radiation Therapy, Inc., a wholly-owned subsidiary of AUA (“Ocean”), for a purchase price of approximately $35 million in cash. Ocean provides image guided radiation therapy (“IGRT”) technical services to AUA’s IGRT cancer treatment center. We borrowed $35 million under the revolver under our senior credit facility to finance the acquisition.

On October 10, 2008, we amended our senior credit facility, to increase the dollar amount of permitted acquisitions under the acquisitions negative covenant of our credit facility from $30 million to $48 million during any twelve month period commencing on or after April 18, 2008 and prior to March 31, 2009 (which dollar amount of permitted acquisitions will decrease back to $30 million during any twelve month period commencing after March 31, 2009), provided that any such acquisitions will be subject to the prior written approval of the administrative agent under our credit facility.

On October 8, 2008, pursuant to a $10 million stock repurchase program adopted by our Board of Directors in October 2008, in a private transaction, we repurchased 1.7 million shares of our common stock from Prides Capital Partners, L.L.C. for an aggregate purchase price of $3,740,000.

-18-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

Forward-Looking Statements

The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding our expectations, hopes, intentions or strategies regarding the future. You should not place undue reliance on forward-looking statements. All forward-looking statements included in this report are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. It is important to note that our actual results could differ materially from those in the forward-looking statements. In addition to any risks and uncertainties specifically identified below and in the text surrounding forward-looking statements in this report, you should review the risk factors described in our most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission, for factors that could cause our actual results to differ materially from those presented.

Statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “will”, “would”, “should”, “plans”, “likely”, “expects”, “anticipates”, “intends”, “believes”, “estimates”, “thinks”, “may”, and similar expressions, are forward-looking statements. The following important factors, in addition to those referred to above, could affect the future results of the health care industry in general, and us in particular, and could cause those results to differ materially from those expressed in such forward-looking statements:

• uncertainties in our establishing or maintaining relationships with physicians and hospitals;

• the impact of current and future laws and governmental regulations;

• uncertainties inherent in third party payors’ attempts to limit health care coverages and levels of reimbursement;

• the effects of competition and technological changes;

• the availability (or lack thereof) of acquisition or combination opportunities; and

• general economic, market or business conditions.

General

We provide healthcare services and medical devices, primarily to the urology marketplace. We have two reportable segments: urology services and medical products.

Urology Services. Our lithotripsy services are provided principally through limited partnerships or other entities that we manage, which use lithotripsy devices. In 2007, physicians who are affiliated with us used our lithotripters to perform approximately 48,000 procedures in the U.S. We do not render any medical services. Rather, the physicians do.

-19-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

We have two types of contracts, retail and wholesale, that we enter into in providing our lithotripsy services. Retail contracts are contracts where we contract with the hospital and private insurance payors. Wholesale contracts are contracts where we contract only with the hospital. The two approaches functionally differ in that, under a retail contract, we generally bill for the entire non-physician fee for all patients other than governmental pay patients, for which the hospital bills the non-physician fee. Under a wholesale contract, the hospital generally bills for the entire non-physician fee for all patients. In both cases, the billing party contractually bears the costs associated with the billing service, including pre-certification, as well as non-collection. The non-billing party is generally entitled to its fees regardless of whether the billing party actually collects the non-physician fee. Accordingly, under the wholesale contracts where we are the non-billing party, the hospital generally receives a greater proportion of the total non-physician fee to compensate for its billing costs and collection risk. Conversely, under the retail contracts where we generally provide the billing services and bear the collection risk, we receive a greater portion of the total non-physician fee.

Although the non-physician fee under both retail and wholesale contracts varies widely based on geographical markets and the identity of the third party payor, we estimate that nationally, on average, our share of the non-physician fee was roughly $2,100, for each of the first nine month periods of 2008 and 2007. At this time, we do not anticipate a material shift between our retail and wholesale arrangements, or a material change in our share of the non-physician fee.

As the general partner of limited partnerships or the manager of other types of entities, we also provide services relating to operating our lithotripters, including scheduling, staffing, training, quality assurance, regulatory compliance, and contracting with payors, hospitals and surgery centers.

Also in the urology segment, we provide treatments for benign and cancerous conditions of the prostate. In treating benign prostate disease, we deploy three technologies: (1) photo-selective vaporization of the prostate (PVP), (2) trans-urethral needle ablation (TUNA), and (3) trans-urethral microwave therapy (TUMT) in certain partnerships. All three technologies apply an energy source which reduces the size of the prostate gland. In September 2007, we completed the sale of our Rocky Mountain Prostate business, which represented almost our entire TUMT treatment operations. For treating prostate and other cancers, we use a procedure called cryosurgery, a process which uses a double freeze thaw cycle to destroy cancers cells.

We recognize urology revenue primarily from the following sources:

• Fees for urology treatments. A substantial majority of our urology revenue is derived from fees related to lithotripsy treatments performed using our lithotripters. We, through our partnerships or other entities, facilitate the use of our equipment and provide other support services in connection with these treatments at hospitals and other health care facilities. The professional fee payable to the physician performing the procedure is generally billed and collected by the physician. Benign prostate disease and prostate cancer treatment services are billed in the same manner as our lithotripsy services under either retail or wholesale contracts. These services are also primarily performed through limited partnerships or other entities, which we manage.

-20-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

• Fees for managing the operation of our lithotripters and laser devices. Through our partnerships and otherwise directly by us, we provide services related to operating our lithotripters and lasers and receive a management fee for performing these services.

Medical Products. We sell and maintain lithotripters and related spare parts and consumables. We are also the exclusive U.S. distributor of the Revolix branded laser. The operations of our pathology laboratories are also included in our medical products segment.

• Fees for maintenance services. We provide equipment maintenance services to our partnerships as well as outside parties. These services are billed either on a time and material basis or at a fixed contractual rate, payable monthly, quarterly, or annually. Revenues from these services are recorded when the related maintenance services are performed.

• Fees for equipment sales, consumable sales and licensing applications. We sell and maintain lithotripters and we distribute the Revolix laser and we also manufacture and sell consumables related to the lithotripters. With respect to some lithotripter sales, in addition to the original sales price, we receive a licensing fee from the buyer of the lithotripter for each patient treated with such lithotripter. In exchange for this licensing fee, we provide the buyer of the lithotripter with certain consumables. All the sales for equipment and consumables are recognized when the related items are delivered. Revenues from licensing fees are recorded when the patient is treated. In some cases, we lease certain equipment to our partnerships, as well as third parties. Revenues from these leases are recognized on a monthly basis or as procedures are performed.

• Fees for anatomical pathology services. We provide anatomical pathology services primarily to the urology marketplace. Revenues from these services are recorded when the related laboratory procedures are performed.

Recent Developments

On October 10, 2008, we entered into a Stock Purchase Agreement with Atlantic Urological Associates (“AUA”), pursuant to which we purchased the outstanding shares of capital stock of Ocean Radiation Therapy, Inc., a wholly-owned subsidiary of AUA (“Ocean”), for a purchase price of approximately $35 million in cash. Ocean provides image guided radiation therapy (“IGRT”) technical services to AUA’s IGRT cancer treatment center. Also on October 10, 2008, we drew $35 million under our revolving line of credit to finance this acquisition.

On October 8, 2008, pursuant to a $10 million stock repurchase program adopted by our Board of Directors in October 2008, in a private transaction, we repurchased 1.7 million shares of our common stock from Prides Capital Partners, L.L.C. for an aggregate purchase price of $3,740,000.

-21-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

Effective September 30, 2008, Ross Goolsby resigned his position as our Chief Financial Officer. Richard A. Rusk assumed the duties of interim Chief Financial Officer effective on September 30, 2008. Mr. Rusk continues to retain his responsibilities as Vice President, Controller, Treasurer, and Secretary.

On July 15, 2008, we acquired UroPath, LLC (“UroPath”) for $7.5 million in cash. Founded in 2003, UroPath is a leading provider of anatomical pathology laboratory services in the U.S. with locations in Florida, Texas, and Pennsylvania.

On June 16, 2008, we sold the office building in which our principal executive offices are located for approximately $6,750,000. We entered into a lease agreement for new office space. We relocated our principal executive offices in late September 2008.

Critical Accounting Policies and Estimates.

Management has identified the following critical accounting policies and estimates:

Impairments of goodwill and other intangible assets are both a critical accounting policy and estimate that require judgment and are based on assumptions of future operations. We are required to test for impairments at least annually or if circumstances change that would reduce the fair value of a reporting unit below its carrying value. We test for impairment of goodwill during the fourth quarter. We have two reporting units, urology services and medical products. The fair value of each reporting unit is estimated using a combination of the income, or discounted cash flows, approach and the market approach, which utilizes comparable companies’ data. Because we have recognized goodwill based solely on our controlling interest, the fair value of each reporting unit also relates only to our controlling interest. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying value of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. Both the income approach and the market approach require significant assumptions to determine the fair value of each reporting unit. The significant assumptions used in the income approach include estimates of our future revenues, profits, capital expenditures, working capital requirements, operating plans, industry data and other relevant factors. The significant assumptions utilized in the market approach include the determination of appropriate market comparables, the estimated multiples of revenue, EBIT and EBITDA a willing buyer is likely to pay, and the estimated control premium a willing buyer is likely to pay. For a discussion of our 2007 and 2006 goodwill impairments and the specific assumptions used in the income and market approaches in the 2007 and 2006 analyses, see footnote C to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2007.

-22-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

A second critical accounting policy and estimate which requires judgment of management is the estimated allowance for doubtful accounts and contractual adjustments. We have based our estimates on historical collection amounts, current contracts with payors, current changes of the facts and circumstances relating to these matters and certain negotiations with related payors.

A third critical accounting policy is consolidation of our investment in partnerships or limited liability companies (LLCs) where we, as the general partner or managing member, exercise effective control, even though our ownership is less than 50%. The consolidated financial statements include our accounts, our wholly-owned subsidiaries, entities more than 50% owned and limited partnerships or LLCs where we, as the general partner or managing member, exercise effective control, even though our ownership is less than 50%. The related agreements provide us with broad powers. The other parties do not participate in the management of the entity and do not have the substantial ability to remove us. Investment in entities in which our investment is less than 50% ownership and we do not have significant control are accounted for by the equity method if ownership is between 20%-50%, or by the cost method if ownership is less than 20%. With respect to partnerships and LLCs where we exercise effective control but own less than 50%, we have reviewed each of the underlying governing agreements for such entities and determined we have effective control; however, if it was determined this control did not exist, these investments would be reflected on the equity method of accounting. Although this would change individual line items within our consolidated financial statements, it would have no effect on our net income and/or total stockholders’ equity.

Nine months ended September 30, 2008 compared to the Nine months ended September 30, 2007

Our total revenues for the nine months ended September 30, 2008 increased $17,036,000 as compared to the same period in 2007. Revenues from our urology services segment increased $15,704,000 (17%) in the first nine months of 2008 as compared to the same period in 2007. Revenues from our lithotripsy business increased $3,537,000 for the first nine months of 2008 as compared to the same period in 2007, and revenues from our prostate business increased $12,167,000 in the first three quarters of 2008 as compared to the same period in 2007. Revenues from our AMPI acquisition, which was effective April 1, 2008, were the primary driver in the increased prostate revenues. Prostate revenues from AMPI entities totaled $12.5 million in nine months of of 2008. Revenues from our recent lithotripsy acquisitions accounted for our increased lithotripsy business as same stores revenues were comparable to 2007. Revenues for our medical products segment for the nine month period ended September 30, 2008 increased $1,465,000 as compared to the same period in 2007. We sold 2 lithotripters and no tables in the first nine months of 2008. We sold 7 lithotripters and 28 tables during the same period in 2007. Revenues from our Claripath laboratory which commenced operations in January 2006, totaled $3,830,000 and $2,412,000 for the nine months ended September 30, 2008 and 2007, respectively. Revenues from our Uropath acquisition, which was effective July, 10, 2008 totaled $720,000 in 2008.

Our costs of services and general and administrative expenses for the nine months ended September 30, 2008 increased $7,712,000 (11%) compared to the same period in 2007. Our cost of services associated with our urology services operations increased $7,163,000 (18%) in the first nine months of 2008 as compared to the same period in 2007. The primary cause of this increase relates to cost of services at our new AMPI entities, whose costs totaled $8,619,000 in 2008, partially offset by an overall decrease in cost of services of $1,456,000 attributed to our organic urology business. This decrease in our organic business costs is primarily related to the write off of a certain payable at one of our partnerships in the first quarter of 2008 of approximately $700,000 which was recorded against operating expenses and $250,000 received at one of our partnerships related to damages suffered during hurricane Katrina. Our cost of services associated with our medical products operations for the first nine months of 2008 decreased $1,109,000 (14%) compared to the same period in 2007. This decrease is due to lower cost of sales on fewer device sales in the period, partially offset by approximately $1,452,000 in increased expenses at our Claripath lab which has experienced significant growth year over year and $652,000 in expenses at our new Uropath labs. A significant portion of medical products costs relate to providing maintenance services to our urology services segment and are allocated to the urology services segment. In the future, we expect margins in medical products to continue to vary significantly from period to period based on the mix of intercompany and third-party sales. Our selling, general and administrative costs for the nine months ended September 30, 2008 increased $1,227,000 compared to the same period in 2007. This increase primarily relates to compensation expenses of $2.4 million related to restricted stock grants to employees which vested as performance goals were reached in the second and third quarters of 2008, partially offset by a gain of $415,000 realized on the sale of the building that housed our corporate headquarters and savings on group medical costs of approximately $360,000 from the prior year.

-23-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

In the first nine months of 2007, we had a loss from discontinued operations of $111,000 attributable to our RMPT and HIFU operations. Our RMPT business, was sold on September 28, 2007.

Depreciation and amortization expense increased $431,000 in the first nine months of 2008 as compared to the same period in 2007, primarily due to the addition of our new AMPI entities.

Minority interest in consolidated income for the nine month period ended September 30, 2008 increased $7,382,000 compared to the same period in 2007, as a result of an increase in income at our existing urology partnerships and minority interest expense at our new AMPI entities.

Provision for income taxes for the first nine months of 2008 increased $774,000 compared to the same period in 2007 due to the increase in our taxable net income during the same periods, partially offset by a decrease in our effective tax rate. For the next several years, we will only be an alternative minimum tax payer as we will utilize our existing net operating loss carry forwards to offset any current taxes payable.

Three months ended September 30, 2008 compared to the three months ended September 30, 2007

Our total revenues for the three months ended September 30, 2008 increased $8,816,000 as compared to the same period in 2007. Revenues from our urology services segment increased $7,510,000 (24%) in the third quarter of 2008 as compared to the same period in 2007. Revenues from our lithotripsy business increased $1,279,000 for the third quarter of 2008 as compared to the same period in 2007, and revenues from our prostate business increased $6,231,000 in the third quarter of 2008 as compared to the same period in 2007. Revenues from our AMPI acquisition, which was effective April 1, 2008, were the primary driver in the increased prostate revenues. Prostate revenues from AMPI entities totaled $6.3 million in the third quarter of 2008. Revenues from our recent lithotripsy acquisitions accounted for our increased lithotripsy business as same stores revenues were comparable to 2007. Revenues for our medical products segment for the quarter ended September 30, 2008 increased $1,460,000 as compared to the same period in 2007. We sold 1 lithotripter and no tables during the third quarter of 2008. We sold 3 lithotripters and no tables during the same period in 2007. Revenues from our Claripath laboratory which commenced operations in January 2006, totaled $1,469,000 and $919,000 for the quarters ended September 30, 2008 and 2007, respectively. Revenues from our Uropath acquisition, which was effective July, 10, 2008 totaled $720,000 in the third quarter of 2008.

-24-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

Our costs of services and general and administrative expenses for the three months ended September 30, 2008 increased $4,834,000 (21%) compared to the same period in 2007. Our cost of services associated with our urology services operations increased $3,739,000 (28%) in the third quarter of 2008 as compared to the same period in 2007. The primary cause of this increase relates to cost of services related to our new AMPI entities, whose costs totaled $4,464,000 in the third quarter of 2008 partially offset by savings in numerous other cost categories, including gains on sales of assets. Our cost of services associated with our medical products operations for the third quarter of 2008 increased $221,000 (8%) compared to the same period in 2007. The primary cause of this increase is due to approximately $637,000 in increased expenses at our Claripath lab which experienced significant growth year over year as well as $652,000 in expenses at our new Uropath labs, partially offset by lower cost of sales due to fewer device sales in the quarter. A significant portion of medical products costs relate to providing maintenance services to our urology services segment and are allocated to the urology services segment. In the future, we expect margins in medical products to continue to vary significantly from period to period based on the mix of intercompany and third-party sales. Our selling, general and administrative costs as of September 30, 2008 increased $548,000 compared to the same period in 2007. This increase primarily relates to $561,000 in compensation expenses related to restricted stock grants to employees.

In the third quarter of 2007, we had a gain from discontinued operations of $135,000 attributable to our RMPT and HIFU operations. Our RMPT business, was sold on September 28, 2007.

Depreciation and amortization expense increased $326,000 in the third quarter of 2008 as compared to the same period in 2007, primarily due to the addition of our new AMPI entities.

Interest income increased $559,000 in the third quarter of 2008 as compared to the third quarter in 2007. We realized $723,000 of interest income in the third quarter 2008 from the final settlement of an IRS audit related to certain tax uncertainties from the HealthTronics-Prime merger in 2004.

Minority interest in consolidated income for the three month period ended September 30, 2008 increased $3,338,000 compared to the same period in 2007, as a result of an increase in income at our existing urology partnerships and minority interest expense at our new AMPI entities.

-25-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

Provision for income taxes in the third quarter of 2008 increased $500,000 compared to the same period in 2007 due to an increase in our taxable income in 2008. For the next several years, we will only be an alternative minimum tax payer as we will utilize our existing net operating loss carry forwards to offset any current taxes payable.

Liquidity and Capital Resources

Cash Flows

Our cash and cash equivalents were $18,434,000 and $25,198,000 at September 30, 2008 and December 31, 2007, respectively. Our subsidiaries generally distribute all of their available cash quarterly, after establishing reserves for estimated capital expenditures and working capital. For the nine months ended September 30, 2008 and 2007, our subsidiaries distributed cash of approximately $42,797,000 and $35,697,000, respectively, to minority interest holders.

Cash provided by our operations, before minority interest, was $51,305,000 for the nine months ended September 30, 2008 and $45,564,000 for the nine months ended September 30, 2007. For the nine months ended September 30, 2008 compared to the same period in 2007, fee and other revenue collected increased by $14,798,000 due primarily to increased revenues from our acquisitions. Cash paid to employees, suppliers of goods and others for the nine months ended September 30, 2008 increased by $8,692,000 compared to the same period in 2007. This fluctuation is primarily attributable to increased operating expenses from our acquisitions and significant pay down of certain accrued expenses related to our AMPI acquisition.

Cash used by our investing activities for the nine months ended September 30, 2008, was $17,513,000. We utilized $17,270,000 in 2008 to acquire interest in certain entities. Approximately $10 million of that cash was used to acquire AMPI and $6.3 million to acquire Uropath. In addition we increased our interest in certain existing litho partnerships. We purchased equipment and leasehold improvements totaling $8,762,000 in 2008, $3,774,000 of which were for additional Revolix lasers. Cash used by our investing activities for the nine months ended September 30, 2007, was $12,480,000. We utilized approximately $7,976,000 in cash in 2007 for acquisitions; our Keystone partnership represented $7.8 million of these costs. We also, purchased equipment and leasehold improvements totaling $6,838,000 in 2007.

Cash used in our financing activities for the nine months ended September 30, 2008, was $40,556,000, primarily due to distributions to minority interests of $42,797,000 and payments on notes payable of $10,561,000 offset by borrowings on notes payable of $13,547,000. Cash used in our financing activities for the nine months ended September 30, 2007, was $37,486,000, primarily due to distributions to minority interests of $35,697,000 and net payments on notes payable of $1,937,000.

Accounts receivable as of September 30, 2008 increased $4,893,000 from December 31, 2007. This increase relates primarily to our purchases of AMPI and Uropath, whose accounts receivable at acquisition totaled $3,072,000 and $1,040,000, respectively.

-26-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

Inventory as of September 30, 2008, totaled $9,980,000 and decreased $241,000 from December 31, 2007.

Senior Credit Facility

Our senior credit facility is comprised of a five-year $60 million revolving line of credit and a $125 million senior secured term loan B due 2011. We entered into this senior credit facility in March 2005 and amended it in April and October 2008. The loan bears interest at a variable rate equal to LIBOR + 1.25 to 2.25% or prime + .25 to 1.25%. On July 31, 2006, we used a portion of the proceeds from the sale of our specialty vehicle manufacturing segment to repay the term loan B in full. As of September 30, 2008, we had $6 million drawn on the revolving line of credit. On October 10, 2008 we drew an additional $35 million related to our acquisition of Ocean. Our senior credit facility contains covenants that, among other things, limit our ability to incur debt, create liens, make investments, sell assets, pay dividends, make capital expenditures, make restricted payments, enter into transactions with affiliates, and make acquisitions. In addition, our facility requires us to maintain certain financial ratios. We were in compliance with the covenants under our senior credit facility as of September 30, 2008.

On April 14, 2008, we amended our senior credit facility to (1) increase the revolving line of credit from $50 million to $60 million, (2) create an exception to the restricted payments negative covenant of the senior credit facility to enable us to repurchase up to $10 million of our common stock, through a stock repurchase program or otherwise, (3) increase the dollar amount of permitted acquisitions under the acquisitions negative covenant of the senior credit facility from $25 million to $30 million during any twelve month period beginning after April 14, 2008 and (4) create an exception from the calculation of such permitted acquisitions basket for our acquisition of AMPI.

On October 10, 2008, we amended our senior credit facility, to increase the dollar amount of permitted acquisitions under the acquisitions negative covenant from $30 million to $48 million during any twelve month period commencing on or after April 18, 2008 and prior to March 31, 2009 (which dollar amount of permitted acquisitions will decrease back to $30 million during any twelve month period commencing after March 31, 2009), provided that any such acquisitions will be subject to the prior written approval of the administrative agent under the senior credit facility.

Other

Other long term debt. As of September 30, 2008, we had notes payable totaling $6.1 million related to equipment purchased by our limited partnerships. These notes payable are paid down from the cash flows of the related partnerships. They generally bear interest at LIBOR or prime plus a certain premium and have various due dates over the next three years.

Unrecognized Tax Benefits: In late September 2008, the Internal Revenue Service completed examinations of certain of our previously filed federal income tax returns. As a result of these examinations, the $2.3 million of previously unrecognized tax benefits we had were recognized and recorded as a reduction to goodwill.

-27-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

General

The following table presents our contractual obligations as of September 30, 2008 (in thousands):

	Payments due by period
Contractual Obligations	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Long Term Debt	$	12,112	$	2,804	$	8,785	$	139	$	384
Operating Leases (1)		10,928		2,596		3,953		2,675		1,704
Non-compete contracts (2)		91		61		30		-		-
Total	$	23,131	$	5,461	$	12,768	$	2,814	$	2,088

(1)	Represents operating leases in the ordinary course of our business.
(2)	Represents an obligation of $21 due to an employee of Medstone, at a rate of $4 per month continuing until February 28, 2009, and an obligation of $70 due to a previous employee of ours, at a rate of $3 per month until June 15, 2010.

In addition, the scheduled principal repayments for all long term debt as of September 30, 2008 are payable as follows:

	($ in thousands)
2008	$	2,804
2009		7,905
2010		880
2011		125
2012		14
Thereafter		384
Total	$	12,112

Our primary sources of cash are cash flows from operations and borrowings under our senior credit facility. Our cash flows from operations and therefore our ability to make scheduled payments of principal, or to pay the interest on, or to refinance our indebtedness, or to fund planned capital expenditures or possible future share repurchases, will depend on our future performance, which is subject to general economic, financial, competitive, legislative, regulatory and other factors. Likewise, our ability to borrow under our senior credit facility will depend on these factors, which will affect our ability to comply with the covenants in our credit facility and our ability to obtain waivers for, or otherwise address, any noncompliance with the terms of our credit facility with our lenders. Our ability to borrow under our senior credit facility also depends on the ability and willingness of lenders under our senior credit facility to meet their funding commitments, especially in light of the current turmoil in the credit markets. If any of the lenders under our senior credit facility fail to meet such commitments, we could be required to borrow from other sources at a higher cost or we may be required to sell some of our assets to meet our liquidity requirements.

We intend to grow our urology services operations primarily through forming new operating subsidiaries in new markets as well as by mergers and acquisitions. We plan to grow our medical products segment by offering new equipment and services at our lab and expanding our customer base. We intend to fund the purchase price for future acquisitions and developments using borrowings under our senior credit facility and cash flows from our operations. In addition, we may use shares of our common stock in such acquisitions where appropriate.

-28-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

We continue to look at strategic acquisition opportunities and believe conditions in the market favor our strong financial position, national platform of urologist relationships, and diversification within the urology services space.

Based upon the current level of our operations and anticipated cost savings and revenue growth, we believe that cash flows from our operations and available cash, together with available borrowings under our senior credit facility, will be adequate to meet our future liquidity needs both for the short term and for at least the next twelve months. However, there can be no assurance that our business will generate sufficient cash flows from operations, that we will realize our anticipated revenue growth and operating improvements or that future borrowings will be available under our senior credit facility in an amount sufficient to enable us to service our indebtedness or to fund our other liquidity needs. In addition, the current turmoil in the equity and credit markets could limit demand for our services and products and affect the overall availability and cost of capital. The impact of the crises on our ability to obtain financing in the future, and the cost and terms of such financing, is unclear.

Inflation

Our operations are not significantly affected by inflation because we are not required to make large investments in fixed assets. However, the rate of inflation will affect certain of our expenses, such as fuel costs and employee compensation and benefits.

Recently Issued Accounting Pronouncements

In May 2008, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS No. 162”), The Hierarchy of Generally Accepted Accounting Principles. SFAS 162 identifies the sources of accounting principles and the framework for selecting the principles used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles in the United States (the GAAP hierarchy). SFAS 162 will become effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles. Based on our current operations, we do not expect that the adoption of SFAS 162 will have a material impact on our financial position or results of operations.

In December 2007, the FASB issued Statement of Financial Accounting Standards (“SFAS”) No. 141 (revised 2007), "Business Combinations", (“SFAS 141R”). SFAS 141R establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, including goodwill, the liabilities assumed and any non-controlling interest in the acquiree. The Statement also establishes disclosure requirements to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS 141R is effective for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. The impact of adopting SFAS 141R will be dependent on the future business combinations that we may pursue after its effective date.

-29-

Item 2 — Management’s Discussion and Analysis
of Financial Condition and
Results of Operations

In December 2007, the FASB issued SFAS No. 160, "Noncontrolling Interests in Consolidated Financial Statements-an amendment of ARB No. 51" (“SFAS 160”). This Statement amends ARB 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. SFAS 160 requires companies to report a noncontrolling interest in a subsidiary as equity. Additionally, companies are required to include amounts attributable to both the parent and the noncontrolling interest in the consolidated net income and provide disclosure of net income attributable to the parent and to the noncontrolling interest on the face of the consolidated statement of income. This Statement clarifies that after control is obtained, transactions which change ownership but do not result in a loss of control are accounted for as equity transactions. Prior to this Statement being issued, decreases in a parent’s ownership interest in a subsidiary could be accounted for as equity transactions or as transactions with gain or loss recognition in the income statement. A change in ownership of a consolidated subsidiary that results in a loss of control and deconsolidation would result in a gain or loss in net income. SFAS 160 is effective for fiscal years beginning on or after December 15, 2008 with earlier adoption prohibited. The adoption of SFAS 160 will revise our presentation of consolidated financial statements and further impact will be dependent on our future changes in ownership in subsidiaries after the effective date.

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities – Including an amendment of FASB Statement No. 115” ("SFAS 159"). SFAS 159 expands the use of fair value accounting to many financial instruments and certain other items. The fair value option is irrevocable and generally made on an instrument-by-instrument basis, even if a company has similar instruments that it elects not to measure based on fair value. SFAS 159 is effective for fiscal years beginning after November 15, 2007. The adoption of SFAS 159 did not have a material impact on our financial position or results of operations.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" (“SFAS 157”). SFAS 157 defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. SFAS 157 is effective for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. In December 2007, the FASB released a proposed FASB Staff Position (FSP FAS 157-b-Effective Date of FASB Statement No. 157) which, if adopted as proposed, would delay the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). In February 2008, the FASB issued FASB Staff Position FAS 157-2, “Effective Date of FASB Statement No. 157” (the “FSP”). The FSP delayed, for one year, the effective date of FAS 157 for all nonfinancial assets and liabilities, except those that are recognized or disclosed in the financial statements on at least an annual basis. The implementation of SFAS No. 157 for financial assets and financial liabilities, effective January 1, 2008, did not have a material impact on our consolidated financial position and results of operations.

-30-

Item 3 — Quantitative and Qualitative Disclosures
About Market Risk

Interest Rate Risk

As of September 30, 2008, we had long-term debt (including current portion) totaling $12,112,000, of which $5,242,000 had fixed rates of 5% to 9%, and $6,870,000 incurred interest at a variable rate equal to a specified prime rate. We are exposed to some market risk due to the remaining floating interest rate debt totaling $6,870,000. We make monthly or quarterly payments of principal and interest on $681,000 of the floating rate debt. An increase in interest rates of 1% would result in a $7,000 annual increase in interest expense on this existing principal balance.

-31-

Item 4 – Controls and Procedures

As of September 30, 2008, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and our Interim Chief Financial Officer (our principal financial officer), we evaluated the effectiveness of our disclosure controls and procedures (as defined under Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on this evaluation, our Chief Executive Officer and our Interim Chief Financial Officer concluded that, as of September 30, 2008, our disclosure controls and procedures were effective.

There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, such internal control over financial reporting.

-32-

PART II

OTHER INFORMATION

-33-

Item 1A. Risk Factors.

In addition to the other information set forth in this report, you should carefully consider the factors discussed under “Risk Factors” in Part I, Item 1 in our Annual Report on Form 10-K for the year ended December 31, 2007, which could materially affect our business, financial condition or future results. There are no material changes from the risk factors disclosed in our 2007 Form 10-K, except as set forth below.

Our lenders may be unable or unwilling to fund their commitments under our senior credit facility.

Our senior credit facility includes a revolving line of credit under which we may regularly draw funds. Many U.S. financial institutions are having difficulty maintaining regulatory capital at levels required for additional lending, and some institutions are experiencing liquidity shortfalls. If some of the lenders participating in our senior credit facility fail to meet their funding commitments, we could be required to borrow from other sources at a higher cost or we may be required to monetize some of our assets to meet our liquidity requirements, which could have an adverse effect on our financial position and results of operations.

The current turmoil in the equity and credit markets could limit demand for our services and products and affect the overall availability and cost of capital.

The current turmoil in the equity and credit markets could limit demand for our services and products, and affect the overall availability and cost of capital. At this time, it is unclear whether and to what extent the actions taken by the U.S. government, including, without limitation, the passage of the Emergency Economic Stabilization Act of 2008 and other measures currently being implemented or contemplated, will mitigate the effects of the crisis. While we have no immediate need to access the equity or credit markets at this time, the impact of the current crisis on our ability to obtain financing in the future, and the cost and terms of the financing, is unclear. No assurances can be given that the effects of the current crisis will not have a material adverse effect on our business, financial condition and results of operations.

The risks described in our Annual Report on Form 10-K and above are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In September 2008, with respect to the vesting of restricted stock awards based on the achievement of performance criteria, three of our officers used some of the vested shares of the restricted stock awards (under the terms of the restricted stock awards) to pay their tax withholding obligations associated with such vesting. A total of 26,399 shares of our common stock were paid to us in respect of such tax withholding obligations. The terms of the restricted stock awards provide that the value of the restricted shares used to pay the tax withholding obligations will be based on the closing price per share of our common stock on the trading day immediately preceding the vesting date, as reported on the Nasdaq Global Select Market.

-34-

In October 2008, our Board of Directors approved up to $10 million of repurchases of our common stock. Under the repurchase program, we anticipate that the stock will be repurchased through privately negotiated transactions or on the open market. We intend to comply with the SEC’s Rule 10b-18, and the repurchases will be subject to market conditions, applicable legal requirements, and other factors. We are not obligated to purchase any shares under the repurchase program. On October 8, 2008, pursuant to the stock repurchase program, in a private transaction, we repurchased 1.7 million shares of our common stock from Prides Capital Partners, L.L.C. for an aggregate purchase price of $3,740,000.

Item 6. Exhibits.

         10.1
                  
                  

         10.2*
                  
         31.1*

         31.2*

         32.1*

         32.2* Termination and Consulting Agreement, dated September 19, 2008, by and between HealthTronics, Inc. and Ross A. Goolsby (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 22, 2008).

Form of director restricted stock award agreement.

Certification of Chief Executive Officer

Certification of Chief Financial Officer

Certification of Chief Executive Officer

Certification of Chief Financial Officer

*    Filed herewith.

-35-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

                                                     



Date: November 6, 2008



                                                     
                                                     
                                                      HEALTHTRONICS, INC.







By: /s/ Richard A. Rusk                                
      Richard A. Rusk
      Interim Chief Financial Officer

-36-

EX-10

EXHIBIT 10.2

HEALTHTRONICS, INC.
DIRECTOR RESTRICTED STOCK AWARD AGREEMENT

        This Director Restricted Stock Award Agreement (the “Agreement”), made as of the ____ day of ____________, 20____ (the “Grant Date”) by and between HealthTronics, Inc. (the “Company”) and _______________ (the “Grantee”), evidences the grant by the Company of an Award of Restricted Stock (the “Award”) to the Grantee on such date and the Grantee’s acceptance of the Award in accordance with the provisions of the Company 2004 Equity Incentive Plan, as amended or restated from time to time (the “Plan”). The Company and the Grantee agree as follows:

        1.    Basis for Award. This Award is made under the Plan pursuant to Section 9 thereof.

        2.    Stock Awarded.

        (a)     The Company hereby awards to the Grantee, in the aggregate, __________ (_______) Shares (“Restricted Stock”), which shall be subject to the restrictions and conditions set forth in the Plan and in this Agreement.

        (b)     Each certificate issued in respect of the Restricted Stock shall be registered in the Grantee’s name and deposited by the Grantee, together with a share power endorsed in blank, with the Company and shall bear the following (or a similar) legend:

        “THE TRANSFERABILITY OF THIS CERTIFICATE AND THE COMMON STOCK REPRESENTEDHEREBY ARE SUBJECT TO THE TERMS AND CONDITIONS (INCLUDING FORFEITURE)CONTAINED IN THE HEALTHTRONICS, INC. 2004 EQUITY INCENTIVE PLAN AND THEDIRECTOR RESTRICTED STOCK AWARD AGREEMENT ENTERED INTO BETWEEN THEREGISTERED OWNER AND HEALTHTRONICS, INC. IN RESPECT OF SUCH STOCK.”

At the expiration of the restrictions, the Company shall redeliver to the Grantee (or the Grantee’s legal representative, beneficiary or heir) share certificates for the Restricted Stock deposited with it without any legend except as otherwise provided by the Plan, this Agreement or as otherwise required by applicable law. The Grantee shall have the right to receive dividends on and to vote the Restricted Stock while it is held in custody except as otherwise provided by the Plan. Notwithstanding the foregoing, the Company shall retain custody of all securities or other property (other than regular cash dividends) distributed by the Company in respect of the Restricted Stock (“Retained Distributions”) subject to the restrictions set forth in this Agreement and such Retained Distributions shall be subject to the same restrictions on terms and conditions as are applicable to such Restricted Stock.

        (c)     Except as provided in the Plan or this Agreement, the restrictions on the Restricted Stock covered by this Agreement are that the stock will be forfeited by the Grantee and all of the Grantee’s rights to such stock shall immediately terminate without any payment or consideration by the Company, in the event of any sale, assignment, transfer, hypothecation, pledge or other alienation of such Restricted Stock made or attempted, whether voluntary or involuntary, and if involuntary whether by process of law in any civil or criminal suit, action or proceeding, whether in the nature of an insolvency or bankruptcy proceeding or otherwise.

        3.    Vesting. The restrictions described in Section 2 of this Agreement will lapse with respect to ____________ shares of the Restricted Stock on the _______ anniversary of the Grant Date, with respect to _______ shares of the Restricted Stock on the _________ anniversary of the Grant Date, with respect to ____________ shares of the Restricted Stock on the ____________ anniversary of the Grant Date, and with respect to ____________ shares of the Restricted Stock on the _______ anniversary of the Grant Date, provided the Grantee is still serving as a member of the Board of Directors of the Company on such vesting dates. If the Grantee ceases to serve as a member of the Board of Directors of the Company for any reason at any time prior to the vesting dates, the unvested Restricted Stock shall automatically be forfeited upon such cessation of service.

        4.    Compliance with Laws and Regulations. The issuance and transfer of Restricted Stock shall be subject to compliance by the Company and the Grantee with all applicable requirements of securities laws and with all applicable requirements of any stock exchange on which the Restricted Stock may be listed at the time of such issuance or transfer. The Grantee understands that the Company is under no obligation to register or qualify the Restricted Stock with the Securities and Exchange Commission (“SEC”), any state securities commission or any stock exchange to effect such compliance.

        5.    Tax Withholding.

        (a)     The Grantee agrees that, subject to clause 5(b) below, no later than the date as of which the restrictions on the Restricted Stock shall lapse with respect to all or any of the Restricted Stock covered by this Agreement, the Grantee shall pay to the Company (in cash or Restricted Stock held by the Grantee whose Fair Market Value on the day preceding the date the Restricted Stock vests is equal to the amount of the Grantee’s tax withholding liability) any federal, state or local taxes of any kind required by law to be withheld, if any, with respect to the Restricted Stock for which the restrictions shall lapse. The Company or its affiliates shall, to the extent permitted by law, have the right to deduct from any payment of any kind otherwise due to the Grantee any federal, state or local taxes of any kind required by law to be withheld with respect to the shares of Restricted Stock.

        (b)     If the Grantee properly elects, within thirty (30) days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the Fair Market Value as of the Grant Date of the Restricted Stock granted hereunder pursuant to Section 83(b) of the Code, the Grantee shall pay to the Company or the appropriate tax authority, or make other arrangements satisfactory to the Administrator to pay to the Company or the appropriate tax authority in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Restricted Stock. If the Grantee fails to make such payments, the Company or its affiliates shall, to the extent permitted by law, have the right to deduct from any payment of any kind otherwise due to the Grantee any federal, state or local taxes of any kind required by law to be withheld with respect to such Restricted Stock.

2

        6.    No Right to Continued Service as a Director. Nothing in this Agreement shall be deemed by implication or otherwise to impose any limitation on any right of the Company or the Company’s shareholders to remove Grantee as a director of the Company, any right of the Nominating Committee of the Company to determine not to nominate Grantee for election as a director of the Company, or any right of the shareholders of the Company to decide not to elect Grantee as a director of the Company.

        7.    Representations and Warranties of Grantee. The Grantee represents and warrants to the Company that:

        (a)    Agrees to Terms of the Plan. The Grantee has received a copy of the Plan and has read and understands the terms of the Plan and this Agreement, and agrees to be bound by their terms and conditions. The Grantee acknowledges that there may be adverse tax consequences upon the vesting of Restricted Stock or disposition of the Restricted Stock once vested, and that the Grantee should consult a tax adviser prior to such time.

        (b)    Cooperation. The Grantee agrees to sign such additional documentation as may reasonably be required from time to time by the Company.

        8.    Adjustment Upon Changes in Capitalization. In the event of a Change in Capitalization under Section 14 of the Plan, the Administrator may make appropriate adjustments to the number and class of shares relating to Restricted Stock as it deems appropriate, in its sole discretion, to preserve the value of this Award. The Administrator’s adjustment shall be made in accordance with the provisions of Section 14 of the Plan and shall be effective and final, binding and conclusive for all purposes of the Plan and this Agreement.

        9.    Governing Law; Modification. This Agreement shall be governed by the laws of the State of Georgia without regard to the conflict of law principles. The Agreement may not be modified except in writing signed by both parties.

        10.    Defined Terms. Except as otherwise provided herein, or unless the context clearly indicates otherwise, capitalized terms used but not defined herein have the definitions as provided in the Plan. The terms and provisions of the Plan are incorporated herein by reference, and the Grantee hereby acknowledges receiving a copy of the Plan. In the event of a conflict or inconsistency between the discretionary terms and provisions of the Plan and the provisions of this Agreement, this Agreement shall govern and control.

        11.    Miscellaneous. The masculine pronoun shall be deemed to include the feminine, and the singular number shall be deemed to include the plural unless a different meaning is plainly required by the context.

[Signature page follows]

3

        IN WITNESS WHEREOF, the parties hereto have signed this Agreement as of the date first above written.

HEALTHTRONICS, INC.


By: ___________________________________________
Name: _________________________________________
Title: ________________________________________



GRANTEE



By: _________________________________________
Name:_________________________________________

S-1

EX-31

Exhibit 31.1

CERTIFICATION

I, James S. B. Whittenburg, President and Chief Executive Officer of HealthTronics, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of HealthTronics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2008
                                         
                                          By: /s/ James S. B. Whittenburg          
       James S. B. Whittenburg
      President and Chief Executive Officer
      

EX-31

Exhibit 31.2

CERTIFICATION

I, Richard A. Rusk, Interim Chief Financial Officer of HealthTronics, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of HealthTronics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2008
                                         
                                          By: /s/ Richard A. Rusk          
       Richard A. Rusk
      Interim Chief Financial Officer
      

EX-32

Exhibit 32.1

Certification of
Chief Executive Officer
of HealthTronics, Inc.

This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the quarterly report on Form 10-Q (the “Form 10-Q”) for the quarter ended September 30, 2008 of HealthTronics, Inc., a Georgia corporation (the “Issuer”).

I, James S. B. Whittenburg, President and Chief Executive Officer of the Issuer, certify that to the best of my knowledge:

(i) the Form 10-Q fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

(ii) the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer.

Dated: November 6, 2008

/s/ James S. B. Whittenburg          
James S. B. Whittenburg
President and Chief Executive Officer
HealthTronics, Inc.

The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Form 10-Q or as a separate disclosure document.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Issuer and will be retained by the Issuer and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32

Exhibit 32.2

Certification of
Chief Financial Officer
of HealthTronics, Inc.

This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the quarterly report on Form 10-Q (the “Form 10-Q”) for the quarter ended September 30, 2008 of HealthTronics, Inc., a Georgia corporation (the “Issuer”).

I, Richard A. Rusk, Interim Chief Financial Officer of the Issuer, certify that to the best of my knowledge:

(i) the Form 10-Q fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

(ii) the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer.

Dated: November 6, 2008

/s/ Richard A. Rusk          
Richard A. Rusk
Interim Chief Financial Officer
HealthTronics, Inc.

The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Form 10-Q or as a separate disclosure document.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Issuer and will be retained by the Issuer and furnished to the Securities and Exchange Commission or its staff upon request.